CTIS2022-503007-22-00进行中（未招募）1 期
A Randomized, Double-Blind, Phase II Study of BMS-986315 and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-line Treatment for Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) - CA0471009
Bristol-Myers Squibb Services Unlimited Company0 个研究点目标入组 196 人开始时间: 2023年9月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 196
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male and female participants must be = 18 years of age or local age of majority at the time of signing the informed consent. Participants must have NSCLC with Stage IV or recurrent disease following multimodal therapy for locally advanced disease. Study treatment must be first-line therapy for Stage IV or recurrent disease. Participants in all parts of the study must have measurable disease per RECIST v1.1; an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; and a life expectancy of at least 3 months at the time of first dose.
排除标准
- •Exclusion Criteria (All Study Parts): Untreated symptomatic central nervous system metastases. Participants with EGFR/ALK/ROS1/NTRK/MET/BRAF/RET mutations amenable to targeted therapies. Participants with any known medical condition that, in the investigator’s opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
研究者
相似试验
进行中（未招募）
1 期
Study of BMS-986207 in Combination with Nivolumab and Ipilimumab in Participants with Stage IV NSCLCon-Small Cell Lung CancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2021-000039-29-PLBristol-Myers Squibb International Corporation240
进行中（未招募）
1 期
Study of BMS-986207 in Combination with Nivolumab and Ipilimumab in Participants with Stage IV NSCLCSmall Cell Lung CancerEUCTR2021-000039-29-ESBristol-Myers Squibb International Corporation240
进行中（未招募）
1 期
Study of BMS-986207 in Combination with Nivolumab and Ipilimumab in Participants with Stage IV NSCLCon-Small Cell Lung CancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2021-000039-29-DEBristol-Myers Squibb International Corporation240
进行中（未招募）
1 期
Study of BMS-986207 in Combination with Nivolumab and Ipilimumab in Participants with Stage IV NSCLCSmall Cell Lung CancerEUCTR2021-000039-29-BEBristol-Myers Squibb International Corporation240
进行中（未招募）
不适用
A phase II study to determine the activity of BMS-354825 in subjects with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia who have disease that is resistant to high dose imatinib mesylate (Gleevec) or who are intolerant of imatinibChronic myeloid leukemiaMedDRA version: 6.1Level: HLTClassification code 10024296EUCTR2004-002601-69-ITBRISTOL-M.SQUIBB240